HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted disease with increasing prevalence and profound ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.